[HTML][HTML] Hepatic PTP4A1 ameliorates high-fat diet-induced hepatosteatosis and hyperglycemia by the activation of the CREBH/FGF21 axis

B Hwang, MG Kwon, MJ Cho, NK Lee, J Lee… - Theranostics, 2023 - ncbi.nlm.nih.gov
Precise regulation of kinases and phosphatases is crucial for human metabolic
homeostasis. This study aimed to investigate the roles and molecular mechanisms of protein …

[HTML][HTML] SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care—An Indian Perspective

KMP Kumar, AG Unnikrishnan, P Jariwala… - Indian Journal of …, 2024 - journals.lww.com
The prevalence and burden of diabetes are on the rise in India, making it 'the diabetes
capital of the world'. Comorbidities such as obesity, cardiovascular (CV) complications …

Exploring the gamut of receptor tyrosine kinases for their promise in the management of non-alcoholic fatty liver disease

S Bhave, HK Ho - Biomedicines, 2021 - mdpi.com
Recently, non-alcoholic fatty liver disease (NAFLD) has emerged as a predominant health
concern affecting approximately a quarter of the world's population. NAFLD is a spectrum of …

Role of ammonia and glutamine in the pathogenesis and progression of metabolic dysfunction‐associated steatotic liver disease: A systematic review

B Njei, YA Al‐Ajlouni, P Ameyaw… - Journal of …, 2024 - Wiley Online Library
Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects over 30% of the
global population, with a significant risk of advancing to liver cirrhosis and hepatocellular …

Triglyceride-Targeted Molecularly Imprinted Polymers Activate Lipophagy via Cargo Exchange for Nonalcoholic Fatty Liver Disease Treatment

Y Wen, P Weng, Y Li, L Yang, C Li… - ACS Applied Polymer …, 2024 - ACS Publications
Lipid accumulation is a prominent pathologic feature of nonalcoholic fatty liver disease
(NAFLD), which is due to imbalances in triglycerides metabolism. However, none of the …

Role of resmetirom, a liver-directed, thyroid hormone receptor beta-selective agonist, in managing non-alcoholic steatohepatitis: a systematic review and meta …

D Dutta, ABM Kamrul-Hasan, E Mondal, L Nagendra… - Endocrine Practice, 2024 - Elsevier
Background Resmetirom, a liver-directed, thyroid hormone receptor beta-selective agonist,
has recently been approved to treat non-alcoholic steatohepatitis (NASH). This meta …

[HTML][HTML] The therapeutic perspective of NAD+ precursors in age-related diseases

T Iqbal, T Nakagawa - Biochemical and Biophysical Research …, 2024 - Elsevier
Nicotinamide adenine dinucleotide (NAD+) is the fundamental molecule that performs
numerous biological reactions and is crucial for maintaining cellular homeostasis. Studies …

Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota

L Chen, L Zhang, S Liu, H Hua, L Zhang… - Microbiology …, 2024 - Am Soc Microbiol
Numerous studies have supported that nonalcoholic fatty liver disease (NAFLD) is highly
associated with gut microbiota dysbiosis. Ling-Gui-Zhu-Gan decoction (LG) has been …

Common Denominator of MASLD and Some Non-Communicable Diseases

K Ferenc, S Jarmakiewicz-Czaja… - Current Issues in …, 2024 - mdpi.com
Currently, steatohepatitis has been designated as metabolic dysfunction-associated
steatohepatitis (MASLD). MASLD risk factors mainly include metabolic disorders but can …

[HTML][HTML] MAFLD and glomerular hyperfiltration in subjects with prediabetes, visceral obesity and “preserved” kidney function: A cross-sectional study

A Parvanova, M Abbate, AM Yanez… - Diabetes research and …, 2023 - Elsevier
Aims To investigate the prevalence of metabolic dysfunction-associated fatty liver disease
(MAFLD) in prediabetes, visceral obesity, and preserved kidney function, and explore …